[go: up one dir, main page]

DE60117701D1 - Testverfahren für agonisten oder antagonisten der bindung von dynorphin a an den mas-rezeptor - Google Patents

Testverfahren für agonisten oder antagonisten der bindung von dynorphin a an den mas-rezeptor

Info

Publication number
DE60117701D1
DE60117701D1 DE60117701T DE60117701T DE60117701D1 DE 60117701 D1 DE60117701 D1 DE 60117701D1 DE 60117701 T DE60117701 T DE 60117701T DE 60117701 T DE60117701 T DE 60117701T DE 60117701 D1 DE60117701 D1 DE 60117701D1
Authority
DE
Germany
Prior art keywords
agonists
antagonists
binding
dynorphine
test procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60117701T
Other languages
English (en)
Other versions
DE60117701T2 (de
Inventor
Sultan Ahmad
Eric Grazzini
Paola Lembo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE60117701D1 publication Critical patent/DE60117701D1/de
Application granted granted Critical
Publication of DE60117701T2 publication Critical patent/DE60117701T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486Analgesics, e.g. opiates, aspirine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406Neurotransmitters
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/665Assays involving proteins derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/916Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/988Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60117701T 2000-12-22 2001-12-19 Testverfahren für agonisten oder antagonisten der bindung von dynorphin a an den mas-rezeptor Expired - Fee Related DE60117701T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25797700P 2000-12-22 2000-12-22
US257977P 2000-12-22
PCT/SE2001/002854 WO2002052267A1 (en) 2000-12-22 2001-12-19 A method of assaying for agonists or antagonist of dynorphin a binding to the mas receptor

Publications (2)

Publication Number Publication Date
DE60117701D1 true DE60117701D1 (de) 2006-05-04
DE60117701T2 DE60117701T2 (de) 2006-09-21

Family

ID=22978581

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60117701T Expired - Fee Related DE60117701T2 (de) 2000-12-22 2001-12-19 Testverfahren für agonisten oder antagonisten der bindung von dynorphin a an den mas-rezeptor

Country Status (7)

Country Link
US (1) US7078177B2 (de)
EP (1) EP1346221B1 (de)
JP (1) JP2004516036A (de)
AT (1) ATE320005T1 (de)
CA (1) CA2430719A1 (de)
DE (1) DE60117701T2 (de)
WO (1) WO2002052267A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0502497A (pt) * 2005-06-28 2007-02-06 Univ Minas Gerais uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017689A (en) * 1989-07-06 1991-05-21 Arizona Technology Development Corporation Dynorphin analogs specific for kappa opioid receptors
SE9704836D0 (sv) 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor

Also Published As

Publication number Publication date
ATE320005T1 (de) 2006-03-15
US20040171080A1 (en) 2004-09-02
CA2430719A1 (en) 2002-07-04
JP2004516036A (ja) 2004-06-03
EP1346221A1 (de) 2003-09-24
EP1346221B1 (de) 2006-03-08
WO2002052267A1 (en) 2002-07-04
US7078177B2 (en) 2006-07-18
DE60117701T2 (de) 2006-09-21

Similar Documents

Publication Publication Date Title
DE69835225D1 (de) Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
ATE377606T1 (de) Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren
EA200600773A1 (ru) Антагонисты мускариновых ацетилхолиновых рецепторов
DE60222396D1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
EA199800913A1 (ru) Кальцилитические соединения
PT1009732E (pt) 1-amino-alquilciclo-hexanos antagonistas do receptor nmda
DE60040212D1 (de) Effiziente parallele prüfung von integrierten schaltungsvorrichtungen, unter verwendung einer bekannten guten schaltung, um erwartete antworten zu erzeugen
EA199900630A1 (ru) Антагонисты рецепторов витронектина
GT200900187A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso los mismos
ATE243993T1 (de) Verwendung von 5ht3 antagonisten zum fördern der darmspülung
EA200501724A1 (ru) Соединения, специфичные к меланокортиновым рецепторам
EA200300593A1 (ru) Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора
DE50011178D1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
DE60121557D1 (de) Metabolite von estrogen-agonisten/-antagonisten
DE60114027D1 (de) Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion
IS5641A (is) Azabísýklískir 5HT1 viðtaka bindlar
ATE260278T1 (de) 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression
DE60117701D1 (de) Testverfahren für agonisten oder antagonisten der bindung von dynorphin a an den mas-rezeptor
DE60210989D1 (de) Der ligand für den g-protein gekoppelten rezeptor gpr86 und seine verwendungen
NO20006320L (no) Cykliske somatostatin-analoger
TR200002072T2 (tr) Spiropiperidin türevleri
DE69920436D1 (de) Simulierte testverbindung zur untersuchung von drehschlagwerkzeugen
ATE408144T1 (de) Assays
DE50015432D1 (de) Prüfeinrichtung zum prüfen von langgestreckten gegenständen
ATE426807T1 (de) Proteomanalyse verfahren zum drogen vergleich

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee